news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

In modern obstetrics and gynecology practice, timely diagnosis of preeclampsia is essential to safeguard the health of pregnant women and fetuses. Preeclampsia is a hypertensive disease specific to pregnancy that may lead to serious maternal and fetal complications. The application of immunodiagnostic technology in this field provides an effective means to monitor and predict the development of this complex disease, thereby achieving early intervention and optimizing treatment outcomes.

The picture comes from the Internet

The occurrence of preeclampsia is not only related to genetic factors, but also affected by a variety of biomarkers. These markers include specific proteins, enzymes, cytokines and biochemical molecules, whose abnormal expression in the blood of pregnant women can indicate potential risks and pathological progression. For example, an abnormal increase in the ratio of soluble vascular endothelial growth factor receptor (sFlt-1) and placental growth factor (PlGF) is an important early warning sign of preeclampsia.

Using these immune markers, scientists and clinicians can more accurately assess a pregnant woman's risk of developing preeclampsia. In recent years, detection technologies based on these markers have developed significantly. For example, through a simple blood test, high-risk pregnant women can be identified early, and preventive measures such as lifestyle adjustments and medical interventions can be taken in time to reduce the incidence and severity of preeclampsia.